# AmTech Bioengineering

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amtech-bioengineering-ltd

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.amtechbe.com
- Latest round: Series A (Aug 23, 2021)
- Investors on record: 1

## About

Based in Shenzhen, China and founded in 2017, AmTech Bioengineering Ltd., Inc. is a developer of biomedical and focuses on the production, sales and service in vitro diagnostic products. It has a trading company for the import and export of raw materials and products in Hong Kong, and a research and development center in Santiago. It also has 2600 square meters of office, research and development and GMP production base in Shenzhen. There are nearly 100 team members. The chairman of the board Dr. Xiaoru Chen, he was graduated from Johns Hopkins University. In August 2021, the company raised more than RMB 10 million in series A+ funding from Oriental Fortune Capital.

The company provides the products of biological and chemical raw materials, in vitro diagnostic reagent and automatic analyzer. It also provides the technology of protein engineering includes recombinant protein expression service, protein purification service and molecular biology services.

The latest funding will be used to expand the marketing team and market channels, improve the production and after-sales service system, and accelerate the research and development of products.

## Funding rounds

- Series A, Aug 23, 2021 — Oriental Fortune Capital

## Investors

- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A